Navigation Links
Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
Date:11/5/2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that it has been awarded over $920,000 in grants through the U.S. government's Qualifying Therapeutic Discovery Project, which provides tax credits and grants to projects that show significant potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years.  

Pervasis is a clinical stage company focused on developing breakthrough therapies with the potential to improve outcomes following common vascular surgical and interventional procedures, such as arteriovenous access, angioplasties, stents and peripheral and coronary bypass grafts—the failure of which result in serious complications and a significant increase in medical costs. There are no currently approved therapies that directly target the underlying physiological processes leading to serious vascular complications, including inflammation, thrombosis (the formation of a blood clot inside a blood vessel) and restenosis (the re-narrowing of a coronary artery after it has been treated with angioplasty or stenting).

Pervasis' therapies harness the power of the endothelium, the thin layer of cells that lines the interior surface of blood vessels, which has a well-understood role in regulating many of the body's healing processes, including vascular repair. Because these endothelial formulations secrete several key factors involved in combating inflammation and restenosis, they may also be applicable to other therapeutic fields where surgical or interventional procedures are required, including inflammatory disease, orthopedic injury and cancer.

The grants awarded to Pervasis span several therapeutic fields for which the company's therapies have application including:

  • Development of PVS-10200 for Peripheral Artery Disease ($244,479.25)
  • Development of Vascugel® to Sustain Arteriov
    '/>"/>

  • SOURCE Pervasis Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
    2. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
    3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
    4. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
    5. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
    6. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
    7. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
    8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
    9. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
    10. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
    11. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... 2015 PharmaEngine, Inc. (TWO:4162) today announced ... MACK ) with its sublicensing partner, Baxter ... that Baxter has submitted a marketing authorization application ... MM-398 (irinotecan liposome injection), also known as "nal-IRI," ... who have been previously treated with gemcitabine-based therapy. ...
    (Date:5/4/2015)... 2015  Oncobiologics, Inc., a biotherapeutics company focused ... has completed the construction of its GMP commercial ... Cranbury, New Jersey . ... designed to utilize multiple technologies that enable rapid ... the use of the latest single-use technologies, the ...
    (Date:5/4/2015)... , May 4, 2015   HeartWare International, Inc ... invasive, miniaturized circulatory support technologies that are revolutionizing the treatment ... Doug Godshall , is scheduled to present at the ... Las Vegas on Thursday, May 14, ... The live webcast of the Company,s presentation at the conference ...
    Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
    ... I clinical trial in healthy subjects- Study aims ... new vaccine candidate- Initial results expected in Q4 ... by PATHVIENNA, April 7 Intercell AG (VSE: ... trial with the company,s vaccine candidate IC47 to ...
    ... Glycotex, Inc. today announced the completion of a scheduled ... effect of investigational GLYC-101 gel on complete wound closure ... dioxide laser skin resurfacing on the lower eyelid area.The ... study. The comparison of each active arm to placebo ...
    Cached Medicine Technology:Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine 2Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine 3Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 2Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 3
    (Date:5/4/2015)... LiveSchool ” was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... students with good behavior. , Positive re-enforcement is more ... And the good people at LiveSchool have taken note ...
    (Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
    (Date:5/4/2015)... CA (PRWEB) May 04, 2015 In May ... Smalley took his own life. In the wake of this ... the Silent, an organization that exposes the grim reality of ... also a platform for Kirk and Laura to share their ... their tragedy from happening to another family — a mission ...
    (Date:5/4/2015)... Now in its seventh year, the IPC ... made outstanding contributions to the company, to their facilities ... and post-acute care settings. The five award categories are: ... Year, Advanced Practice Clinician of the Year, Newcomer Provider ... Recipients are selected by IPC’s senior management team. , ...
    (Date:5/4/2015)... May 04, 2015 EyeCRO LLC and ... to facilitate development of NM108, a first-in-class small molecule ... to blindness, including Diabetic Retinopathy. The collaboration grants ... by EyeCRO, which can deliver drugs to the front ... , Under the terms of the agreement, EyeCRO ...
    Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3
    ... ROCKFORD, Mich., Aug. 31 Pediatric Wildlife Care Tables, ... answer to an age-old problem for doctors, nurses and healthcare ... , , Constantly in need of ... long relied on bulky rolling computer tables to temporarily stow ...
    ... along with alcohol use, survey shows , MONDAY, Aug. ... are often exercisers. , According to a new University ... the American Journal of Health Promotion , the ... exercise. , "Alcohol users not only exercised more ...
    ... , Politics and Possibilities of Health ... WASHINGTON, Aug. 31 URAC ... that several key policy makers and insurance leaders will lead a discussion, ... Care Landscape," at URAC,s 10th Annual Quality Summit and Exhibit ...
    ... , , , ... (Nasdaq: PPHM ), today announced that noted cancer researcher Bruce ... the design of clinical trials for the bavituximab cancer program. Dr. ... Center, chief of hematology and oncology at MGH and a professor of ...
    ... 31 /PRNewswire-Asia/ -- Sundia MediTech Company, a leading,pharmaceutical ... that,it received the Highest Growth Potential Award from ... announced at the 10th anniversary celebration of,"Focus on ... Vice President,for Process Chemistry and GMP Operations, attended ...
    ... , , , ... medical technology systems integrator transforming critical care, announced that former Veterans ... Board of Advisors. , , Secretary Peake retired ... and commander in several medical posts culminating in his appointment as ...
    Cached Medicine News:Health News:Foldaway Pediatric Point of Care Table Provides Efficient Work Surface Without Compromising Space 2Health News:Drinkers May Exercise More Than Teetotalers 2Health News:Policy Makers Discuss Health Care Reform at URAC Quality Summit 2Health News:Policy Makers Discuss Health Care Reform at URAC Quality Summit 3Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 2Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 3Health News:Peregrine Pharmaceuticals Adds Noted Oncologist Dr. Bruce Chabner as Clinical Advisor to Support Advancement of Its Clinical Programs 4Health News:Sundia Receives the Highest Growth Potential Award from Zhangjiang 2Health News:Former Veterans Affairs Secretary Joins Integrated Medical Systems' Advisory Board 2Health News:Former Veterans Affairs Secretary Joins Integrated Medical Systems' Advisory Board 3
    ... Wampole Laboratories offers a comprehensive line ... for serum and urine in convenient one-step ... offers 2 testing options. Clearview Easy HCG ... a convenient stick format. Clearview HCG ...
    ... line of pregnancy tests including rapid membrane ... one-step stick and cassette formats. The Clearview ... HCG is a 25 mIU urine test ... HCG II provides 25mIU sensitivity for urine ...
    For the quantitative determination of Glycohemoglobin (HbA1) in blood by,cation exchange resin. The test is to be used to monitor long-term glucose,control in diabetes mellitus....
    Rapid turn-around time, results in less than 4 hours...
    Medicine Products: